Notification
No new Notification messages
Hyundai Motor India IPO is Open!
Apply for the Hyundai Motor India IPO through UPI in just minutes
HCL Technologies Q2 Results FY'25
HCL Tech announced its Q2 FY'25 results, revenue jumped by 8.2% YoY at ₹28,862 crores, and Net Income stood at ₹4,235 crores up 10.5% YoY.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
Trade Now, Pay Later with up to 4x Leverage
Never miss a good trading opportunity due to low funds with our MTF feature.

AstraZeneca Gets Approval For Cancer Drug Durvalumab

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

AstraZeneca Pharma India received CDSCO approval to import and distribute Durvalumab (Imfinzi) for an additional cancer treatment. The drug will target NSCLC with chemotherapy in India, expanding its therapeutic applications

AstraZeneca Pharma news today

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab (Imfinzi) for an additional indication in the Indian market. This approval will allow AstraZeneca to bring its cancer drug to patients who require specific treatments for non-small cell lung cancer (NSCLC) in combination with chemotherapy.

This development marks an important step in the company’s efforts to expand its portfolio of cancer treatments available in India.

ASTRAZENECA PHARMA IND LT

Trade

7615.95-81.50 (-1.05 %)

Updated - 15 October 2024
7778.30day high
DAY HIGH
7575.00day low
DAY LOW
25009
VOLUME (BSE)

Expanding cancer treatment options

Durvalumab, marketed as Imfinzi, is already used to treat certain types of cancer globally. The approval from CDSCO opens the door for the drug to be used in combination with chemotherapy as a neoadjuvant treatment. This will be followed by Durvalumab monotherapy after surgery, specifically for patients with resectable NSCLC that involves tumours 4 cm or larger, and node-positive cases.

The approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solutions for infusion. This addition will provide more treatment options for cancer patients in India, helping to address cases where other treatments are ineffective.

Targeting non-small cell lung cancer

The new indication focuses on patients with non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This specific group of patients with resectable tumours will benefit from the combination of Durvalumab and chemotherapy, as well as the continued use of Durvalumab post-surgery.

By expanding the range of its cancer drug treatments, AstraZeneca aims to strengthen its presence in India’s oncology market.

AstraZeneca share price performance

Following this announcement, shares of AstraZeneca Pharma India closed at ₹6,749 on the BSE, reflecting a 1.65% decline. Despite the drop, the company’s stock remains of interest as its ongoing advancements in the pharmaceutical sector continue to make headlines. The approval of Durvalumab for a new indication is expected to contribute to AstraZeneca’s growth in the Indian market.

This approval further establishes AstraZeneca’s commitment to improving cancer treatment options in India, reinforcing its standing in the country's pharmaceutical industry.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text